Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells.
Metastasized and chemoresistant secondary breast cancer treatment commonly shows very low efficacy. A new efficient treatment method is required to overcome the limitation against the secondary breast cancer. In this study, anoikis-resistant breast cancer cells, MDA-MB-231 and MCF-7 were developed as models of chemoresistant and metastatic breast cancer. Doxorubicin encapsulating human serum albumin nanoparticles (HSA+DOX NPs) were fabricated to confirm the benefits of nanoparticles at the treatment of anoikis-resistant breast cancer cells. The side population (SP) fraction in the anoikis-resistant cancer cells was higher than the parental cells. HSA+DOX NPs were more cytotoxic to anoikis-resistant cancer cells than free doxorubicin. The confocal microscope images demonstrated HSA+DOX NPs to deliver more doxorubicin into cells compared to the free doxorubicin by bypassing the drug efflux pump systems of anoikis-resistant cancer cells. In this study, a nanomedicine-based drug delivery carrier shows a potential in treating a metastasized and chemoresistant breast cancer.
Department of Chemical & Biomolecular Engineering, Sogang University, #1 Shinsu-dong, Mapo-gu, Seoul 121-742, Republic of Korea.
Hohyeon
H
Lee
Sunyoung
S
Park
Jong Bin
JB
Kim
Jungwook
J
Kim
Hyuncheol
H
Kim
D023102:Anoikis / Q000187:drug effects*; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000556:secondary; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004317:Doxorubicin / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D018613:Microscopy, Confocal; D053758:Nanoparticles; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology; D012709:Serum Albumin / Q000737:chemistry; D000075462:Serum Albumin, Human; D058985:Side-Population Cells / Q000187:drug effects / Q000473:pathology; D013997:Time Factors
C422455:ALB protein, human; D000903:Antibiotics, Antineoplastic; D012709:Serum Albumin; D004317:Doxorubicin; D000075462:Serum Albumin, Human